年龄、合并症与PSA倍增时间对非转移性去势抵抗性前列腺癌长期竞争性死亡风险的影响
该回顾性研究基于SEARCH数据库1238例2000-2015年诊断的非转移性去势抵抗性前列腺癌(nmCRPC)患者,分析年龄、Charlson合并症指数(CCI)和PSA倍增时间(PSADT)对总体死亡、前列腺癌特异性死亡(PCSM)和其他原因死亡(OCM)竞争风险的影响。结果显示较高CCI与较高OCM风险相关,较慢PSADT与较低PCSM风险相关;PSADT<9个月者PCSM为所有年龄和合并症组的主要死因,而PSADT≥9个月者PCSM与OCM风险相当,但年龄>80岁且CCI≥3者OCM为主要死因。
要点
- nmCRPC患者中位年龄77岁,57%合并症负担较重(CCI>1)。
- PSADT<9个月者前列腺癌特异性死亡为所有年龄和合并症组的主要死因。
- PSADT≥9个月者PCSM与OCM风险相当,但年龄>80岁且CCI≥3者OCM为主。
核心结论
- 在nmCRPC男性中,年龄、合并症和PSADT与死亡风险及死因相关,可能有助于临床预后咨询。
研究设计与样本
- 回顾性分析SEARCH数据库中2000-2015年诊断的1238例nmCRPC患者,采用多变量Cox比例风险模型和竞争风险回归分析。
主要发现
- nmCRPC患者中位年龄77岁,CCI>1者701例(57%)。
- 多变量Cox分析显示较高CCI与较高OCM风险相关,较慢PSADT与较低PCSM风险相关(所有年龄亚组)。
- CCI≥3(对比CCI0)者OCM风险比:年龄<70岁为2.7(95%CI 1.1-6.3),70-79岁为2.0(95%CI 1.1-3.6),≥80岁为2.5(95%CI 1.5-4.0)。
- PSADT≥9个月(对比<9个月)者PCSM风险比:年龄<70岁为0.5(95%CI 0.3-0.9),70-79岁为0.6(95%CI 0.4-0.9),≥80岁为0.6(95%CI 0.4-0.9)。
- 竞争风险曲线显示PSADT<9个月者PCSM为所有年龄和合并症组的主要死因;PSADT≥9个月者PCSM与OCM风险相当,但年龄>80岁且CCI≥3者OCM为主要死因。
临床怎么用
- 临床可利用年龄、CCI和PSADT对nmCRPC患者进行竞争风险分层,辅助预后咨询和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding competing risks for mortality is critical in determining prognosis among men with non-metastatic castration-resistant prostate cancer (nmCRPC), a disease state that often affects older men and has substantial heterogeneity in risk of cancer mortality. We sought to determine the impact of age, comorbidity, and PSA doubling time (PSADT) on competing risks for mortality in men with nmCRPC. METHODS: We conducted a retrospective analysis of 1238 patients diagnosed with nmCRPC in 2000-2015 in the SEARCH database. Multivariable Cox proportional hazards and competing risks regression were used to determine the hazards of overall, prostate cancer-specific (PCSM), and other-cause mortality (OCM) across age, Charlson comorbidity index (CCI), and PSADT subgroups. RESULTS: Men with nmCRPC were elderly (median age 77) and had substantial comorbidity burdens (CCI > 1 n = 701, 57%). Multivariable Cox analysis showed higher CCI was associated with higher hazard of OCM, while slower PSADT was associated with lower hazard of PCSM across all age subgroups. Among those with CCI ≥ 3 (vs. CCI0), the hazard ratio of OCM was 2.7 (95% CI 1.1-6.3), 2.0 (95% CI 1.1-3.6), and 2.5 (95% CI 1.5-4.0) for those aged <70, 70-79, and ≥80, respectively. Among those with PSADT ≥ 9 months (vs. < 9 months), the hazard ratios for PCSM were 0.5 (95% CI 0.3-0.9), 0.6 (95% CI 0.4-0.9), and 0.6 (95% CI 0.4-0.9) for those aged <70, 70-79, and ≥80. Competing risks curves revealed PCSM was the predominant cause of death for those with PSADT < 9 months across all age and comorbidity groups. PCSM and OCM were relatively equal competitors for mortality among those with PSADT≥9 months except those aged > 80 with CCI ≥ 3, in whom OCM was the predominant cause of death. CONCLUSIONS: Among men with nmCRPC, age, comorbidity, and PSADT are associated with risk and cause of death and may assist clinicians in counseling patients regarding cancer prognosis.
引用
- Whitney CA, Howard LE, Freedland SJ, et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 30279582. doi:10.1038/s41391-018-0095-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。